Meet Edson who could access Lu-PSMA in Brazil
After six years of treatments that were no longer [...]
2024 PSMA Conference
Event: 2024 PSMA Conference - PSMA PET and RLT: [...]
Meet Fernando, a prostate cancer patient
At the age of 55, in apparent perfect health [...]
The Michael Hofman Masterclass
Event: The Michael Hofman Masterclass: PSMA - A new era [...]
European Commission approves Pluvicto™
European Commission Approves Pluvicto for PSMA-Positive mCRPC OncLive, Dec 14, [...]
Dr Acosta’s testimonial : A journey living with prostate cancer
Discover Dr. Fernando Acosta’s treatment journey with radiotheranostics in his [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Proven Superior for Metastatic Prostate Cancer
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]
Patient Management with Lu-177–PSMA-617 in the Clinic
Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate [...]
PSMA Theranostics: Current Landscape and Future Outlook
Cancers 2021, 13(16), 4023; https://doi.org/10.3390/cancers13164023, August 10, 2021, by Hanbo [...]